SVB Leerink Upgrades Horizon Therapeutics to Outperform, Lowers Price Target to $80
SVB Leerink analyst David Risinger upgrades Horizon Therapeutics (NASDAQ:HZNP) from Market Perform to Outperform and lowers the price target from $95 to $80.